B. Riley Securities Reiterates Buy on Anika Therapeutics, Lowers Price Target to $17
Anika Therapeutics Inc (ANIK) Q3 2026 Earnings Call Highlights: Revenue Growth and Margin Gains ...
Anika Therapeutics (ANIK) Q3 2026 Earnings Call Transcript
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Anika: Q3 Earnings Snapshot
Anika Reports Third Quarter 2026 Financial Results
Anika Therapeutics Q3 2026 Earnings Call Transcript
Anika Therapeutics Raises FY2026 Sales Guidance from $118.460M-$124.101M to $119.588M-$124.101M vs $121.639M Est
Anika Therapeutics Q3 Adj. EPS $0.29 Beats $0.06 Estimate, Sales $30.594M Beat $29.436M Estimate
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
Anika (ANIK) Q2 2026 Earnings Call Transcript
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.